A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors (GIST)

A Phase I Open-label Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax in Patients With Progressing Gastrointestinal Stromal Tumors (GIST) During Ongoing Second, Third or Fourth Line Treatment With Tyrosine Kinase Inhibition Therapy. A Prospective Single Armed, Open Label Phase I Safety and Efficacy Study

The study is a prospective single armed, open label phase I study. Patients with advanced or metastatic GIST and tumor progression despite ongoing treatment with second, third or fourth line TKI treatment, and with at least one measureable tumor lesion, will be eligible for the study. A maximum of 12 patients will be included in this study. The patients will continue with TKI treatment until the 3 months follow up visit. If further tumor progression TKI will be withdrawn but if stable disease or objective response the patient will continue with TKI until progress. The investigational product Intuvax will be injected into a tumor lesion at two or three treatment occasions; day 1, 14 days (±3 days) after the first vaccination, and 28 days (±3 days) after the second vaccination (patient 7-12 only). Intuvax will be injected in a viable part of the tumor, using ultrasound-guided or CT technique for correct administration.

Study Overview

• Status: Completed
• Conditions: Gastrointestinal Stromal Tumor
• Intervention / Treatment: Biological: Intuvax (ilixadencel)

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden, SE-171 76
    • Department of Breast and Endocrine Surgery, Section of Endocrine and Sarcoma Surgery, Karolinska University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Be informed of the nature of the study and have provided written informed consent.
2. At least 18 years of age.
3. Diagnosis of GIST (according to modified NIH criteria, 2011) where curative excision is no longer an option, i.e. confirmed unresectable or metastatic GIST, and that has progressed on second, third or fourth line tyrosine kinase inhibitor (TKI) treatment.
4. Radiologically measurable tumor(s), i.e at least 3 cm in longest uni-dimensional diameter as measured by CT
5. Clinical and/or CT verified disease progression despite ongoing second, third or fourth line treatment with a TKI
6. Female who has been post-menopausal for more than one (1) year or female of childbearing potential using a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner with combined use of condom and/or birth control pills]) during study participation. Female of childbearing potential must have a negative blood pregnancy test at Screening, and if randomized to vaccination a negative blood or urine pregnancy test within one (1) day before each dose of Intuvax, or Male agreeing to use condoms during the study participation or male having a female partner who is using a highly efficient method of contraception as described above during the partner's study participation.

Exclusion Criteria:

1. Performance status > ECOG 2
2. Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxia or other serious reaction)
3. Known major reaction/adverse event in connection with previous transfusions of blood products
4. Active autoimmune disease requiring treatment with systemic immunosuppressive agents, e.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.
5. Tested positive for HIV
6. Active virus disease (HBV and HCV).
7. Ongoing infection that requires treatment with parenteral antibiotics or antiviral medication
8. Corticosteroid treatment per os exceeding 10mg/day within 7 days prior to the first injection of Intuvax. Inhaled, intranasal and local steroids accepted.

9. Inadequate laboratory parameters, i.e.:

   • B-Leukocyte count < 3.0 x109/L
   • B-Platelet count < 75 x109/L
   • B-Hemoglobin < 100 g/L
   • P-Prothrombincomplex (PK) >1.4
   • P-APT time outside normal limit
10. Previous organ transplantation
11. Pregnant or lactating women
12. Life expectancy less than 3 months.
13. Investigational treatment (within 28 days) prior to the first injection of Intuvax
14. Known blood dyscrasia (bleeding complication)
15. Prior history of invasive cancer within 5 years before screening, except for adequately treated in situ carcinomas or non melanoma skin cancer
16. History of alcohol or substance abuse
17. patient will not be available for follow up assessments
18. Any other reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intuvax (ilixadencel); Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12). Max 10 000 000 allogeneic dendritic cells/ml per injection.	Biological: Intuvax (ilixadencel); Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection; Other Names: ilixadencel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Changes in vital signs (heart rate, blood pressure, body temperature)	Up to 12 months after vaccination 1
Changes in lab parameters (hematology and biochemistry) during the study versus baseline	Up to 12 months after vaccination 1
Adverse events according to CTCAE v 4.03	Up to 12 months after vaccination 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor response by determining changes (PD, SD, PR, CR) in tumor diameter according to mRECIST	Criteria based on the diameter of the contrast-enhanced portions of the tumor	Every 3 months up to 12 months after vaccination 1
Tumor response by determining changes (PD, SD, PR, CR) in tumor diameter according to RECIST 1.1.	Criteria based on the maximal tumor diameter	Every 3 months up to 12 months after vaccination 1
Tumor response by determining changes (PD, SD, PR, CR) in tumor diameter according to Choi criteria	Criteria based on unidimensional tumor size and tumor density on contrast-enhanced CT images.	Every 3 months up to 12 months after vaccination 1
Progression free survival according to mRECIST	Criteria based on the diameter of the contrast-enhanced portions of the tumor	Up to 12 months after vaccination 1
Progression free survival according to RECIST 1.1	Criteria based on the maximal tumor diameter	Up to 12 months after vaccination 1
Progression free survival according to Choi criteria	Criteria based on unidimensional tumor size and tumor density on contrast-enhanced CT images.	Up to 12 months after vaccination 1
Changes in WHO-ECOG score		Up to 12 months after vaccination 1
Levels of autoimmunization parameters	Screening of autoantibodies against nuclear antigens (ANA), including the nuclear antigens SSA, SSB, Sm, RNP, Scl-70, Centromeres and Jo-1	Up to 3 months after vaccination 1
Levels of alloimmunization parameters	Screening of alloantibodies against HLA-A, B, C (MHC-class I) and HLA-DR (MHC-class II) antigens	Up to 3 months after vaccination 1

Collaborators and Investigators

• Sponsor: Mendus
• Investigators: Study Director: Study Director, Mendus

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2016
• Primary Completion (Actual): May 10, 2019
• Study Completion (Actual): May 10, 2019

Study Registration Dates

• First Submitted: January 19, 2016
• First Submitted That Met QC Criteria: February 16, 2016
• First Posted (Estimate): February 22, 2016

Study Record Updates

• Last Update Posted (Actual): July 5, 2019
• Last Update Submitted That Met QC Criteria: July 3, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: GIST
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Neoplasms, Connective Tissue; Gastrointestinal Stromal Tumors
• Other Study ID Numbers: IM-103; 2015-002689-22 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No